Associated Papers
Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer.
Fu Z et al.
Cancer Cell, 2026
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
41351070 (PubMed )
Supplement: 12885_2025_15187_MOESM1_ESM.zip › Supp_Table_1.xlsx › Sheet1
A full-proteome, interaction-specific characterization of mutational hotspots across human cancers.
Chen S et al.
Genome Research, 2022
34963661 (PubMed )
Supplement: supp_gr.275437.121_Supplementary_Table_1.xlsx › Non-recurrent_variants
Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis.
Hoefflin R et al.
Cancers, 2021
33800365 (PubMed )
Supplement: cancers-13-01151-s001.zip › Supplementary_Data_2.xlsx › Cosmic_Annotated_Mutations
Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas.
Campanella NC et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology, 2020
High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.
Nagano M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience.
Hoefflin R et al.
Jco Precision Oncology, 2018
Select a paper to view details